Results 101 to 110 of about 24,524 (277)
Hydrolytic degradation of azimsulfuron, a sulfonylurea herbicide
, 2007 The chemical degradation of the herbicide azimsulfuron was investigated in aqueous solutions at different pH values. The hydrolysis rate, determined by HPLC analyses, was pH dependent and was much faster in acidic than in neutral or weakly basic ...
ANTONIONI, CRISTINA +4 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger +5 more
wiley +1 more source
Sulfonylurea Use Before Stroke Does Not Influence Outcome [PDF]
, 2011 Background and Purpose-Sulfonylureas block nonselective cation channels and lower serum glucose and are neuroprotective in animal models of ischemic stroke. Human data on sulfonylureas in acute stroke are sparse and conflicting.
Higgins, P. +14 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh +2 more
wiley +1 more source
Transport of sulfonylurea herbicides from a barley field in Norway: Field and laboratory studies [PDF]
, 2008 Although the sulfonylurea herbicides have been used for many years worldwide, few field studies have been performed and little is known about the occurrence, fate and transport of sulfonylureas in the field.
Christiansen, Agnethe +6 more
core
Diabetes, Metabolic Syndrome and Obesity, 2016 Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of ...
Hassoun AAK +7 more
doaj
JPMA. The Journal of the Pakistan Medical Association, 2015 This review describes the basic and clinical pharmacology of sulfonylureas. It undertakes a balanced assessment of the advantages and limitations of sulfonylureas, and compares the use of various sulfonylureas in different clinical situations. The authors suggest pragmatic guidance to facilitate safe and effective use of this class of drugs, and thus ...
Sanjay, Kalra, Yashdeep, Gupta
openaire +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim +9 more
wiley +1 more source
The role of pharmacogenetics in the treatment of diabetes mellitus [PDF]
Journal of Medical Biochemistry, 2014 Diabetes mellitus is a heterogeneous group of disorders in which particular disease phenotypes can be characterized by a specific etiology and/or pathogenesis of the disease, but in many cases its classification is greatly impeded due to significant ...
Topić Elizabeta
doaj